Cargando…
Comparison of Clinical Efficacy and Safety between 70–150 µm and 100–300 µm Doxorubicin Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma
Background: This study aimed to compare the efficacy and safety of 70–150 μm doxorubicin drug-eluting bead (DEB) transarterial chemoembolization (TACE) with those of 100–300 μm DEB-TACE as first-line treatment in patients with hepatocellular carcinoma (HCC). Methods: We retrospectively investigated...
Autores principales: | Yi, Jung Woo, Hong, Hyun Pyo, Kim, Myung Sub, Shin, Byung Seok, Kwon, Heon-Ju, Kim, Byung Ik, Sohn, Won |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877410/ https://www.ncbi.nlm.nih.gov/pubmed/35207584 http://dx.doi.org/10.3390/life12020297 |
Ejemplares similares
-
Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma
por: Greco, Giorgio, et al.
Publicado: (2017) -
Response rate and safety in patients with hepatocellular carcinoma treated with transarterial chemoembolization using 40-µm doxorubicin-eluting microspheres
por: Albrecht, Katharina Carolin, et al.
Publicado: (2020) -
Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma
por: Nam, Hee Chul, et al.
Publicado: (2016) -
Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma
por: Kloeckner, Roman, et al.
Publicado: (2015) -
Doxorubicin-loaded Drug-eluting beads Versus Conventional Transarterial Chemoembolization for Nonresectable Hepatocellular Carcinoma
por: Arabi, Mohammad, et al.
Publicado: (2015)